Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

insmed inc. - INSM

INSM

Close Chg Chg %
140.01 -0.20 -0.14%

Open Market

139.81

-0.20 (0.14%)

Volume: 276.45K

Last Updated:

May 5, 2026, 11:11 AM EDT

Trade Now

Company Overview: insmed inc. - INSM

INSM Key Data

Open

$140.86

 Day Range

138.41 - 142.90

52 Week Range

63.81 - 212.75

 Market Cap

$30.22B

Shares Outstanding

215.85M

 Public Float

213.74M

Beta

0.89

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$6.40

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.75M

  

INSM Performance

1 Week
 
 5.07%
 
1 Month
 
 -13.80%
 
3 Months
 
 -6.57%
 
1 Year
 
 115.14%
 
5 Years
 
 329.74%
 

INSM Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 22
Full Ratings ➔

About insmed inc. - INSM

Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. The company was founded in 1988 and is headquartered in Bridgewater, NJ.

INSM At a Glance

Insmed, Inc.
700 US Highway 202/206
Bridgewater, New Jersey 08807-3365
Phone 1-908-977-9900 Revenue 606.42M
Industry Pharmaceuticals: Major Net Income -1,276,775,000.00
Sector Health Technology 2025 Sales Growth 66.734%
Fiscal Year-end 12 / 2026 Employees 1,664
View SEC Filings

INSM Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 57.116
Price to Book Ratio 50.46
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -34.715
Enterprise Value to Sales 56.004
Total Debt to Enterprise Value 0.022

INSM Efficiency

Revenue/Employee 364,436.899
Income Per Employee -767,292.668
Receivables Turnover 4.305
Total Asset Turnover 0.283

INSM Liquidity

Current Ratio 3.827
Quick Ratio 3.545
Cash Ratio 3.05

INSM Profitability

Gross Margin 78.738
Operating Margin -164.04
Pretax Margin -209.713
Net Margin -210.542
Return on Assets -59.526
Return on Equity -249.284
Return on Total Capital -85.405
Return on Invested Capital -83.485

INSM Capital Structure

Total Debt to Total Equity 102.302
Total Debt to Total Capital 50.569
Total Debt to Total Assets 33.383
Long-Term Debt to Equity 99.695
Long-Term Debt to Total Capital 49.28
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Insmed Inc. - INSM

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
245.36M 305.21M 363.71M 606.42M
Sales Growth
+30.19% +24.39% +19.17% +66.73%
Cost of Goods Sold (COGS) incl D&A
60.18M 70.63M 90.79M 128.94M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
24.27M 10.58M 11.01M 16.45M
Depreciation
19.21M 5.53M 5.96M 10.45M
Amortization of Intangibles
5.05M 5.05M 5.05M 6.00M
COGS Growth
+22.31% +17.36% +28.56% +42.01%
Gross Income
185.18M 234.58M 272.91M 477.48M
Gross Income Growth
+32.98% +26.68% +16.34% +74.96%
Gross Profit Margin
+75.47% +76.86% +75.04% +78.74%
2022 2023 2024 2025 5-year trend
SG&A Expense
663.30M 915.51M 1.06B 1.47B
Research & Development
397.52M 571.01M 598.37M 771.09M
Other SG&A
265.78M 344.50M 461.12M 701.17M
SGA Growth
+30.98% +38.02% +15.73% +38.96%
Other Operating Expense
- - - -
-
Unusual Expense
(19.28M) 28.38M 91.92M 251.99M
EBIT after Unusual Expense
(458.85M) (709.31M) (878.49M) (1.25B)
Non Operating Income/Expense
5.14M 43.99M 53.34M 58.81M
Non-Operating Interest Income
11.08M 42.13M 53.31M 60.66M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
26.45M 81.69M 84.91M 83.80M
Interest Expense Growth
-34.66% +208.91% +3.94% -1.32%
Gross Interest Expense
26.45M 81.69M 84.91M 83.80M
Interest Capitalized
- - - -
-
Pretax Income
(480.15M) (747.01M) (910.07M) (1.27B)
Pretax Income Growth
-10.02% -55.58% -21.83% -39.74%
Pretax Margin
-195.69% -244.76% -250.22% -209.71%
Income Tax
1.38M 2.56M 3.71M 5.03M
Income Tax - Current - Domestic
269.00K 378.00K 356.00K 577.00K
Income Tax - Current - Foreign
1.34M 2.23M 3.38M 4.48M
Income Tax - Deferred - Domestic
(231.00K) (54.00K) (29.00K) (27.00K)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(481.53M) (749.57M) (913.77M) (1.28B)
Minority Interest Expense
- - - -
-
Net Income
(481.53M) (749.57M) (913.77M) (1.28B)
Net Income Growth
-10.79% -55.66% -21.91% -39.73%
Net Margin Growth
-196.26% -245.59% -251.24% -210.54%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(481.53M) (749.57M) (913.77M) (1.28B)
Preferred Dividends
- - - -
-
Net Income Available to Common
(481.53M) (749.57M) (913.77M) (1.28B)
EPS (Basic)
-3.9138 -5.3375 -5.5703 -6.4155
EPS (Basic) Growth
-0.95% -36.38% -4.36% -15.17%
Basic Shares Outstanding
123.03M 140.43M 164.04M 199.01M
EPS (Diluted)
-3.9138 -5.3375 -5.5703 -6.4155
EPS (Diluted) Growth
-0.95% -36.38% -4.36% -15.17%
Diluted Shares Outstanding
123.03M 140.43M 164.04M 199.01M
EBITDA
(453.86M) (670.35M) (775.56M) (978.33M)
EBITDA Growth
-33.76% -47.70% -15.69% -26.14%
EBITDA Margin
-184.98% -219.64% -213.24% -161.33%

Snapshot

Average Recommendation BUY Average Target Price 212.70
Number of Ratings 22 Current Quarters Estimate -0.736
FY Report Date 06 / 2026 Current Year's Estimate -2.538
Last Quarter’s Earnings -0.96 Median PE on CY Estimate N/A
Year Ago Earnings -6.42 Next Fiscal Year Estimate 1.176
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 18 18 20 20
Mean Estimate -0.74 -0.52 -2.54 1.18
High Estimates -0.28 0.14 -0.55 4.86
Low Estimate -1.35 -1.08 -5.29 -0.61
Coefficient of Variance -42.23 -61.89 -44.91 104.81

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 19 19 18
OVERWEIGHT 3 3 2
HOLD 0 0 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Insmed Inc. - INSM

Date Name Shares Transaction Value
Mar 6, 2026 Melvin Sharoky Director 242,776 Bona fide gift 0.00
Mar 6, 2026 William H. Lewis Chair and CEO; Director 39,960 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2026 William H. Lewis Chair and CEO; Director 56,332 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2026 William H. Lewis Chair and CEO; Director 301,185 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $147.54 per share 44,436,834.90
Mar 6, 2026 William H. Lewis Chair and CEO; Director 303,313 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $146.66 per share 44,483,884.58
Mar 6, 2026 William H. Lewis Chair and CEO; Director 307,212 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $145.27 per share 44,628,687.24
Mar 6, 2026 William H. Lewis Chair and CEO; Director 309,801 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $144.23 per share 44,682,598.23
Mar 6, 2026 William H. Lewis Chair and CEO; Director 311,884 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $17.16 per share 5,351,929.44
Mar 6, 2026 William H. Lewis Chair and CEO; Director 307,444 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $30.46 per share 9,364,744.24
Feb 26, 2026 Michael A. Smith Chief Legal Officer 67,642 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $155.06 per share 10,488,568.52
Feb 26, 2026 Michael A. Smith Chief Legal Officer 51,871 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $156.53 per share 8,119,367.63
Feb 26, 2026 David Richard Brennan Director 60,933 Bona fide gift 0.00
Feb 26, 2026 Michael A. Smith Chief Legal Officer 76,645 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $17.07 per share 1,308,330.15
Feb 26, 2026 Michael A. Smith Chief Legal Officer 71,793 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $153.93 per share 11,051,096.49
Feb 26, 2026 Michael A. Smith Chief Legal Officer 14,282 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 23, 2026 William H. Lewis Chair and CEO; Director 306,891 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $160.7 per share 49,317,383.70
Jan 23, 2026 William H. Lewis Chair and CEO; Director 75,109 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 23, 2026 William H. Lewis Chair and CEO; Director 53,280 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 14, 2026 Martina Flammer Chief Medical Officer 84,907 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $186.19 per share 15,808,834.33
Jan 14, 2026 William H. Lewis Chair and CEO; Director 81,368 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Insmed Inc. in the News